Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Night night
This doesn’t even deserve to be trading on the OTC let alone Nasdaq
Uh oh
On August 21, 2024, Monopar Therapeutics Inc. (Monopar) issued a press release announcing that Monopar has received Human Research Ethics Committee (HREC) clearance in Australia to commence a Phase 1 therapeutic trial of its novel radiopharmaceutical MNPR-101-Lu.
Some one poke it
And just like that every buyer yesterday in pain
FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment
Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A’s Compelling Potential as Treatment for Advanced Solid Tumors
Don’t blink
Welp….
That chart…. LOL
What they gonna do after this halt
YIKES
Buy high sell low
That was rude
80m plus traded since 8am….
PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study
Almost 40m has traded in last 12 mins LOL
Look at these fraudsters
This is legal LOL
Uh oh
Long halt
Halt up
Don’t blink
Halt up
Yawn….
Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer
50 plus mill day…
Another one
Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer
Lion Group Holding Makes Strategic Investment of Agunua Technology, to Explore New Opportunities in Carbon Finance
VCI Global Announces 44% Revenue Growth in Its Financial Results for the Six Months Ended June 30, 2024; Announces US$10 Million Share Repurchase Program Over 2 Years
7m volume
Short Float 22.29%
Oh geez
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder